<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00268710</url>
  </required_header>
  <id_info>
    <org_study_id>XRP6976J_2503</org_study_id>
    <nct_id>NCT00268710</nct_id>
  </id_info>
  <brief_title>Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]</brief_title>
  <official_title>Multicenter Phase II Study of Taxotere (Docetaxel) Administered Weekly or Every Three Weeks in Combination With Prednisone as Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer (HRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Urologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objectives:&#xD;
&#xD;
        -  To determine the response rate, measurable and non measurable, to Taxotere® in the&#xD;
           second line setting.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To evaluate the overall safety and toxicity of Taxotere®/prednisone combination as&#xD;
           second line therapy in HRPC&#xD;
&#xD;
        -  To evaluate PSA response (PSA: Prostate Specific Antigen)&#xD;
&#xD;
        -  To evaluate symptomatic response&#xD;
&#xD;
        -  To evaluate Quality of life&#xD;
&#xD;
        -  To evaluate patient safety of weekly versus q3 weekly regimens of Taxotere®.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain (pain progression evaluated with the Present Pain Intensity scale form McGill-Melzack questionnaire)</measure>
    <time_frame>During the Study Conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesics (assessed by Pain Medication Log)</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA (PSA response and PSA progression</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor lesion assessment,</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events recorded by the investigator where intensity was according to NCI-CTC criteria: Standard hematology, blood chemistry and clinical exams.</measure>
    <time_frame>from the inform consent signed up to the end of the study</time_frame>
  </secondary_outcome>
  <condition>Prostatic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically/cytologically proven prostate adenocarcinoma&#xD;
&#xD;
          -  Progression or non response with previous chemotherapy regimen (excluding Taxotere®)&#xD;
&#xD;
          -  Received previous mitoxantrone/prednisone or one other chemotherapy regimen including&#xD;
             emcyt +/- vinblastine&#xD;
&#xD;
          -  Castration levels of testosterone (&lt;50 ng/dL )&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Laboratory requirements :&#xD;
&#xD;
               1. Hematology:&#xD;
&#xD;
                    -  Neutrophils ≥ 1.5 x 10^9/L&#xD;
&#xD;
                    -  Hemoglobin &gt; 10 g/dL (prior transfusion permitted).&#xD;
&#xD;
                    -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
               2. Hepatic function:&#xD;
&#xD;
                    -  Total bilirubin &lt; the upper-normal limit of the institution.&#xD;
&#xD;
                    -  ALAT (SGPT) and ASAT (SGOT) ≤ 1.5 times the upper-normal limit of the&#xD;
                       institution.&#xD;
&#xD;
               3. Renal function:&#xD;
&#xD;
                    -  Creatinine ≤1.5 times the upper normal limit (i.e., NCI grade ≤1)&#xD;
&#xD;
          -  No severe or uncontrolled disease&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Chemotherapy within the last 4 weeks&#xD;
&#xD;
          -  Anti-androgen therapy within the last 4 weeks.&#xD;
&#xD;
          -  Prior malignancy except the following: adequately treated non-melanomatous skin cancer&#xD;
             and superficial bladder cancer from which the patient has been disease-free for &gt;2&#xD;
             years.&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs. Participation in another clinical&#xD;
             trial with any investigational drug within 30 days prior to study screening.&#xD;
&#xD;
          -  Treatment with any other anti-cancer therapy (except LHRH agonists) including any&#xD;
             prescribed compounds and/or OTC products for the treatment of prostate cancer must be&#xD;
             stopped prior to study entry.&#xD;
&#xD;
          -  Other serious illness, psychiatric or medical condition that would not permit the&#xD;
             patient to be managed according to the protocol including active uncontrolled&#xD;
             infection and significant cardiac dysfunction.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monique Furlan</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 21, 2005</study_first_submitted>
  <study_first_submitted_qc>December 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2005</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

